Publication number: 20230112499
Abstract: The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and po
Type:
Application
Filed:
December 14, 2020
Publication date:
April 13, 2023
Applicant:
Bayer Aktiengesellschaft
Inventors:
Olaf PANKNIN, Frank SACHER, Nicole SCHMIDT, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Hideki MIYATAKE ONDOZABAL, Holger SIEBENEICHER, Antonius TER LAAK, Hana CERNECKA